Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 3, Pages 654-665
Publisher
Informa UK Limited
Online
2015-10-05
DOI
10.3109/10428194.2015.1071486
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
- (2015) Jorge E. Cortes et al. CANCER
- Omacetaxine mepesuccinate in chronic myeloid leukemia
- (2014) Omar Al Ustwani et al. EXPERT OPINION ON PHARMACOTHERAPY
- Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
- (2014) H. Jean Khoury et al. LEUKEMIA & LYMPHOMA
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
- (2013) H. M. Kantarjian et al. BLOOD
- Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
- (2013) Jorge E. Cortes et al. Clinical Lymphoma Myeloma & Leukemia
- Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
- (2013) F. E. Nicolini et al. HAEMATOLOGICA
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
- (2013) Wesam Ahmed et al. Current Hematologic Malignancy Reports
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
- (2011) Meir Wetzler et al. CURRENT PHARMACEUTICAL DESIGN
- Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
- (2011) E K Allan et al. LEUKEMIA
- Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
- (2010) R. Chen et al. BLOOD
- Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
- (2009) Alfonso Quintás-Cardama et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now